← Steven E. Nissen

Papers by Steven E. Nissen

Page 2 · newest first

51. Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM TrialCirculation Cardiovascular Imaging · 2024
52. Obicetrapib—the Rebirth of CETP Inhibitors?Current Atherosclerosis Reports · 2024
53. Ketamine vs Electroconvulsive Therapy for Treatment-Resistant DepressionJAMA Network Open · 2024
54. Renoprotective Effects of Metabolic Surgery Versus GLP1 Receptor Agonists on Progression of Kidney Impairment in Patients with Established Kidney DiseaseAnnals of Surgery · 2024
55. Obicetrapib on top of maximally tolerated lipid‐modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYNAmerican Heart Journal · 2024
56. Contemporary Management of Obesity: A Comparison of Bariatric Metabolic Surgery and Novel Incretin Mimetic DrugsDiabetes Technology & Therapeutics · 2024
57. Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a)JAMA · 2024
58. A Technology-Assisted Web Application for Consumer Access to a Nonprescription Statin MedicationJournal of the American College of Cardiology · 2024
59. Effect of Testosterone on Progression From Prediabetes to Diabetes in Men With HypogonadismJAMA Internal Medicine · 2024
60. Trends and Outcomes Associated With Bariatric Surgery and Pharmacotherapies With Weight Loss Effects Among Patients With Heart Failure and ObesityCirculation Heart Failure · 2024
61. Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future researchEuropean Journal of Preventive Cardiology · 2024
62. Impact of Bempedoic Acid on Total Cardiovascular EventsJAMA Cardiology · 2024
63. Testosterone Treatment and Fractures in Men with HypogonadismNew England Journal of Medicine · 2024
64. Depressive Syndromes in Men With Hypogonadism in the TRAVERSE Trial: Response to Testosterone-Replacement TherapyThe Journal of Clinical Endocrinology & Metabolism · 2024
65. Impact of Bariatric Surgery on Left Ventricular Structure and FunctionJournal of the American Heart Association · 2023
66. Prostate Safety Events During Testosterone Replacement Therapy in Men With HypogonadismJAMA Network Open · 2023
67. Lipoprotein (a) as a Biomarker for Cardiovascular Diseases and PotentialNew Therapies to Mitigate RiskCurrent Vascular Pharmacology · 2023
68. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trialThe Lancet Diabetes & Endocrinology · 2023
69. Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a)JAMA · 2023
70. Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin IntoleranceCirculation · 2023
71. Safety of bempedoic acid in patients at high cardiovascular risk and with statin intoleranceJournal of clinical lipidology · 2023
72. Efficacy of Testosterone Replacement Therapy in Correcting Anemia in Men With HypogonadismJAMA Network Open · 2023
73. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristicsAmerican Heart Journal · 2023
74. Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled HypertensionJAMA · 2023
75. Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) FormationJAMA · 2023
76. Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal ReductionJAMA Cardiology · 2023
77. Plaque morphology, inflammation, and outcome: cautious and tempered interpretation warrantedEuropean Heart Journal · 2023
78. Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with HypogonadismThe Journal of Clinical Endocrinology & Metabolism · 2023
79. Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant PatientsJAMA · 2023
80. Cardiovascular Safety of Testosterone-Replacement TherapyNew England Journal of Medicine · 2023
81. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major DepressionNew England Journal of Medicine · 2023
82. Comparative Effectiveness of Diabetes Drugs: The Use and Misuse of Observational ResearchAnnals of Internal Medicine · 2023
83. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant PatientsNew England Journal of Medicine · 2023
84. An evaluation of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adultsExpert Review of Cardiovascular Therapy · 2022
85. Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM StudyCirculation Cardiovascular Imaging · 2022
86. Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 WeeksCirculation · 2022
87. Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory BiomarkersJournal of the American College of Cardiology · 2022
88. Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular diseaseSHILAP Revista de lepidopterología · 2022
89. Primary and secondary prevention of atherosclerotic cardiovascular disease: A case-based approachCleveland Clinic Journal of Medicine · 2022
90. Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetesSHILAP Revista de lepidopterología · 2022
91. Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction TherapyJournal of the American College of Cardiology · 2022
92. Association of Bariatric Surgery With Cancer Risk and Mortality in Adults With ObesityJAMA · 2022
93. Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) LevelsJAMA · 2022
94. Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trialEuropean Heart Journal - Cardiovascular Pharmacotherapy · 2022
95. HbA1c, Coronary atheroma progression and cardiovascular outcomesAmerican Journal of Preventive Cardiology · 2022
96. How a New Understanding of Drug or Drug Class Pharmacology Often Drives Drug Development: A Conversation with Steven E. Nissen, MDMethodist DeBakey Cardiovascular Journal · 2022
97. Association of Weight Loss Achieved Through Metabolic Surgery With Risk and Severity of COVID-19 InfectionJAMA Surgery · 2021
98. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE studyAmerican Heart Journal · 2021
99. Plaque microstructures during metformin therapy in type 2 diabetic subjects with coronary artery disease: optical coherence tomography analysisCardiovascular Diagnosis and Therapy · 2021
100. Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic SteatohepatitisJAMA · 2021